Customize your JAMA Network experience by selecting one or more topics from the list below.
Fecal microbiota transplant (FMT) using a single “superdonor” produced high rates of clinical response in patients with irritable bowel syndrome (IBS) in a trial published in Gut. Two previous randomized clinical trials of FMT for IBS had conflicting results.
The study randomized 165 patients to receive either a placebo (30 g of their own feces) or 30 g or 60 g of FMT. The transplant material, obtained from a 36-year-old healthy white man, was stored frozen and administered via gastroscope.
Treatment response, defined as a decrease of 50 or more points on an IBS symptom score, increased with dose, occurring in 23.6% of the placebo group, 76.9% of the 30-g FMT group, and 89.1% of the 60-g FMT group. Fatigue and quality of life also improved in the treatment groups compared with the placebo group, and adverse events were mild.
Choosing a donor with “a favourable specific microbial signature is essential for successful FMT,” the authors wrote.
Slomski A. “Superdonor” Fecal Microbiota Transplant Effective for IBS. JAMA. 2020;323(12):1124. doi:10.1001/jama.2020.2812
Coronavirus Resource Center
Create a personal account or sign in to: